BioN­Tech read­ies for plunge in Covid sales, will boost mR­NA and on­col­o­gy pipelines

BioN­Tech is es­ti­mat­ing €5 bil­lion (near­ly $5.4 bil­lion) in Covid-19 vac­cine sales this year, a marked drop from €17.1 bil­lion ($18.5 bil­lion) in 2022 — and way off an­a­lysts’ ex­pec­ta­tions of around €8 bil­lion ($8.6 bil­lion).

In BioN­Tech’s year-end earn­ings call on Mon­day, it re­port­ed a to­tal of €17.3 bil­lion ($18.7 bil­lion) in 2022 rev­enue, al­most all from vac­cine sales, which in­clude those via its Pfiz­er deal and di­rect sales.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN